50.61
Sanofi Adr stock is traded at $50.61, with a volume of 1.49M.
It is up +0.16% in the last 24 hours and up +5.59% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$50.53
Open:
$50.61
24h Volume:
1.49M
Relative Volume:
0.66
Market Cap:
$124.24B
Revenue:
$43.23B
Net Income/Loss:
$6.79B
P/E Ratio:
12.60
EPS:
4.0174
Net Cash Flow:
$9.17B
1W Performance:
+3.20%
1M Performance:
+5.59%
6M Performance:
-7.07%
1Y Performance:
-8.35%
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
50.61 | 121.56B | 43.23B | 6.79B | 9.17B | 4.0174 |
![]()
LLY
Lilly Eli Co
|
709.82 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
178.93 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
209.50 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
126.82 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
86.08 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
Mar-21-25 | Initiated | Goldman | Neutral |
Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
Jul-26-24 | Reiterated | Argus | Buy |
Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
Jan-16-24 | Resumed | UBS | Buy |
Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
Oct-30-23 | Downgrade | Stifel | Buy → Hold |
Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-13-22 | Resumed | Morgan Stanley | Overweight |
Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
Aug-09-22 | Downgrade | UBS | Buy → Neutral |
May-23-22 | Initiated | SVB Leerink | Outperform |
Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jan-15-21 | Initiated | Deutsche Bank | Sell |
Sep-29-20 | Initiated | Berenberg | Hold |
Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-03-19 | Initiated | Bernstein | Outperform |
Aug-14-19 | Upgrade | UBS | Neutral → Buy |
Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-09-18 | Initiated | Guggenheim | Neutral |
Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
Mar-23-18 | Upgrade | Liberum | Hold → Buy |
Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
MacroGenics Revenue Doubles in Q2 - The Motley Fool
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha
Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com
Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent
Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):